2,4-Disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K

被引:24
作者
Li, Er-dong [1 ,2 ]
Lin, Qiao [1 ,2 ]
Meng, Ya-qi [1 ,2 ]
Zhang, Lu-ye [1 ,2 ]
Song, Pan-pan [1 ,2 ]
Li, Na [1 ,2 ]
Xin, Jing-chao [1 ,2 ]
Yang, Peng [1 ,2 ]
Bao, Chong-nan [1 ,2 ]
Zhang, Dan-qing [1 ,2 ]
Zhang, Yang [1 ,2 ]
Wang, Ji-kuan [1 ,2 ]
Zhang, Qiu-rong [1 ,2 ]
Liu, Hong-min [1 ,2 ]
机构
[1] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Henan, Peoples R China
[2] Collaborat Innovat Ctr New Drug Res & Safety Eval, Zhengzhou 450001, Henan, Peoples R China
基金
中国国家自然科学基金;
关键词
Quinazoline; Breast cancer; EGFR-PI31; BIOLOGICAL EVALUATION; DERIVATIVES; PI3K/AKT/MTOR; GEFITINIB; PATHWAY; DESIGN; GROWTH;
D O I
10.1016/j.ejmech.2019.03.030
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of novel 2,4-disubstituted quinazolines were synthesized and evaluated for their anti-tumor activity against five human cancer cells (MDA-MB-231, MCF-7, PC-3, HGC-27 and MGC-803) using MIT assay. Among them, compound 9n showed the most potent cytotoxicity against breast cancer cells. Compound 9n also significantly inhibited the colony formation and migration of MDA-MB-231 and MCF-7 cells. Meanwhile, compound 9n induced cell cycle arrest at G1 phase and cell apoptosis, as well as increased accumulation of intracellular ROS. Furthermore, compound 9n exerted anti-tumor effects in vitro via decreasing the expression of anti-apoptotic protein Bcl-2 and increasing the pro-apoptotic protein Bax and p53. Mechanistically, compound 9n markedly decreased p-EGFR and p-PI3K expression, which revealed that compound 9n targeted breast cancer cells via interfering with EGFR-PI3K signaling pathway. Molecular docking suggested that compound 9n could indeed bind into the active pocket of EGFR. All the findings suggest that compound 9n might be a valuable lead compound for anti-tumor agents targeting breast cancer cells. (C) 2019 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:36 / 47
页数:12
相关论文
共 32 条
[1]   Synthesis, analgesic and anti-inflammatory evaluation of some novel quinazoline derivatives [J].
Alafeefy, Ahmed M. ;
Kadi, Adnan A. ;
Al-Deeb, Omar A. ;
El-Tahir, Kamal E. H. ;
Al-jaber, Nabila A. .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2010, 45 (11) :4947-4952
[2]   An overview of quinazolines: Pharmacological significance and recent developments [J].
Alagarsamy, V. ;
Chitra, K. ;
Saravanan, G. ;
Solomon, V. Raja ;
Sulthana, M. T. ;
Narendhar, B. .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 151 :628-685
[3]   Kilogram-scale synthesis of a highly selective α1-adrenoceptor antagonist (DL-028A) [J].
Chou, SY ;
Yin, WK ;
Chung, YS ;
Chang, LS ;
Liu, CW ;
Chen, SF ;
Shih, KS .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2002, 6 (03) :273-278
[4]  
Cohen M. H., 2005, ONCOLOGIST, V10, P416
[5]   United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets [J].
Cohen, MH ;
Williams, GA ;
Sridhara, R ;
Chen, G ;
McGuinn, WD ;
Morse, D ;
Abraham, S ;
Rahman, A ;
Liang, CY ;
Lostritto, R ;
Baird, A ;
Pazdur, R .
CLINICAL CANCER RESEARCH, 2004, 10 (04) :1212-1218
[6]  
David R. B., 1994, CRIT REV ONCOL HEMAT, V19, P183
[7]   The PI3K Pathway in Human Disease [J].
Fruman, David A. ;
Chiu, Honyin ;
Hopkins, Benjamin D. ;
Bagrodia, Shubha ;
Cantley, Lewis C. ;
Abraham, Robert T. .
CELL, 2017, 170 (04) :605-635
[8]   Lapatinib plus capecitabine for HER2-positive advanced breast cancer [J].
Geyer, Charles E. ;
Forster, John ;
Lindquist, Deborah ;
Chan, Stephen ;
Romieu, C. Gilles ;
Pienkowski, Tadeusz ;
Jagiello-Gruszfeld, Agnieszka ;
Crown, John ;
Chan, Arlene ;
Kaufman, Bella ;
Skarlos, Dimosthenis ;
Campone, Mario ;
Davidson, Neville ;
Berger, Mark ;
Oliva, Cristina ;
Rubin, Stephen D. ;
Stein, Steven ;
Cameron, David .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (26) :2733-2743
[9]   New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors [J].
Golob-Schwarzl, Nicole ;
Krassnig, Stefanie ;
Toeglhofer, Anna M. ;
Park, Young Nyun ;
Gogg-Kamerer, Margit ;
Vierlinger, Klemens ;
Schroeder, Fabian ;
Rhee, Hyungjn ;
Schicho, Rudolf ;
Fickert, Peter ;
Haybaeck, Johannes .
EUROPEAN JOURNAL OF CANCER, 2017, 83 :56-70
[10]   Hallmarks of Cancer: The Next Generation [J].
Hanahan, Douglas ;
Weinberg, Robert A. .
CELL, 2011, 144 (05) :646-674